CBTN Partners With Day One to Drive New Therapies for Pediatric Brain Tumors
CBTN Partners With Day One to Drive New Therapies for Pediatric Brain Tumors
CBTN's innovative approach ensures data remains open to the global research community while facilitating collaboration with commercial entities like Day One.PHILADELPHIA, Dec. 16, 2024 /PRNewswire/ -- The Children's Brain Tumor Network (CBTN), a consortium of leading pediatric brain tumor research institutions, announces that it has formed a groundbreaking partnership with Day One Biopharmaceuticals (Day One), a company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases. This new partnership between CBTN and Day One aims to accelerate the development of new treatments for children with brain tumors. It leverages the robust Pediatric Brain Tumor Atlas (PBTA), a comprehensive resource containing genomic, clinical, and imaging data from over 7,600 pediatric brain tumor patients. Day One will utilize this data set to design clinical trials.
費城，2024年12月16日 /PRNewswire/ -- 兒童腦腫瘤網絡（CBTN），一家領先的兒科腦腫瘤研究機構的聯盟，宣佈與Day One生物製藥公司（Day One）建立了一項開創性合作伙伴關係，該公司致力於爲所有年齡段的危重疾病患者開發和商業化靶向療法。這一CBTN與Day One之間的新合作旨在加速兒童腦腫瘤新療法的開發。該合作利用了強大的兒科腦腫瘤圖譜（PBTA），這是一個包含7600多名兒科腦腫瘤患者的基因組、臨床和影像數據的綜合資源。Day One將利用這一數據集設計臨床試驗。
"We are deeply grateful for this partnership, which reflects a shared commitment to advancing therapies for children with brain tumors," said Dr. Angela Waanders, LLG Study Chair for the Children's Brain Tumor Network. "Uniting CBTN resources with Day One's innovative approach accelerates the delivery of clinical trials to children worldwide."
"我們對這次合作深表感謝，這體現了共同推進兒童腦腫瘤療法的承諾，"兒童腦腫瘤網絡的LLG研究主席Angela Waanders博士表示。"將CBTN的資源與Day One的創新方法結合，加速了臨床試驗向全球兒童的提供。"
Together, CBTN and Day One aim to accelerate the development of new treatments for children with brain tumors.
CBTN和Day One共同致力於加速爲兒童腦腫瘤開發新療法。
CBTN's innovative approach ensures data remains open to the global research community while facilitating collaboration with commercial entities like Day One.
CBTN的創新方法確保數據對全球研究社區開放，同時促進與Day One等商業實體的合作。
"CBTN's commitment to open access data, coupled with their world-class expertise in pediatric brain tumors, makes them an ideal partner for Day One," said Elly Barry, M.D., chief medical officer, Day One Biopharmaceuticals. "This collaboration should allow us to better design clinical trials to potentially bring new therapies to children in need."
"CBTN對開放數據的承諾，加上他們在兒科腦腫瘤領域的世界級專業知識，使他們成爲Day One的理想合作伙伴，" Day One生物製藥公司的首席醫學官Elly Barry萬.D.表示。"這一合作應使我們能夠更好地設計臨床試驗，潛在地爲需要幫助的兒童帶來新療法。"
The partnership between CBTN and Day One also paves the way for developing trial-ready external control arms in pediatric clinical studies.
CBTN與Day One之間的合作還爲在兒科臨床研究中開發準備就緒的外部對照組鋪平了道路。
About Children's Brain Tumor Network
關於兒童腦腫瘤網絡
CBTN is a collaborative research enterprise created to ensure that no child suffers or dies from a brain tumor. The 35 international member institutions comprising CBTN have enrolled more than 7,000 study participants and more than 70,000 biospecimen samples to create the world's most comprehensive repository of childhood brain tumors. To learn more, visit cbtn.org.
CBTN是一個協作研究企業，旨在確保沒有兒童因腦腫瘤而受苦或死亡。CBTN的35個國際成員機構已經招募了超過7000名研究參與者和超過70000個生物樣本，以建立全球兒童腦腫瘤最全面的數據庫。如需了解更多信息，請訪問cbtn.org。
Press Contact
Whitney Rife
[email protected] | 609-947-6809
新聞聯繫人
惠特尼·裏夫
[email protected] | 609-947-6809
SOURCE Children's Brain Tumor Network
來源：兒童腦腫瘤網絡
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想讓貴公司的資訊在PRNEWSWIRE.COM上特色展示嗎？
譯文內容由第三人軟體翻譯。